Back to Journals » Patient Related Outcome Measures » Volume 5

Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life

Authors Planas R, Martin R, Sospedra M

Received 28 January 2014

Accepted for publication 26 February 2014

Published 4 April 2014 Volume 2014:5 Pages 25—33

DOI https://doi.org/10.2147/PROM.S41768

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3


Raquel Planas, Roland Martin, Mireia Sospedra

Neuroimmunology and MS Research, Department of Neurology, University of Zurich, Zurich, Switzerland

Abstract: Natalizumab was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall tolerability. However, the incidence of treatment-associated progressive multifocal leukoencephalopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-term studies confirm the considerable and sustained efficacy of natalizumab, although the PML complication still threatens one of the most successful treatments available for RRMS. During these years, considerable progress has been made in identification of risk factors that allow more effective management of PML risk. In addition, long-term studies to define better when to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are ongoing, and hopefully will improve management and will allow natalizumab to remain as a valuable therapeutic option for patients with highly active RRMS.

Keywords: therapy, progressive multifocal leukoencephalopathy, multiple sclerosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]